MicroPort CardioFlow Medtech Corp. (HK:2160)
:2160
Want to see HK:2160 full AI Analyst Report?
Top Page
MicroPort CardioFlow Medtech Corp.
(2160)
Select Model
Select Model
Rating:40Underperform
Price Target:
HK$1.00
▼(-20.00% Downside)
Action:Downgraded
Date:06/23/26
The score is constrained primarily by weak financial quality—widening losses, negative cash flow, and a sharp step-up in leverage that increases balance-sheet risk. Technicals further weigh on the score as the stock is in a steep downtrend with very weak momentum. Valuation provides limited offset because the negative P/E reflects ongoing losses and no dividend yield is available.
Positive Factors
Steady revenue growth
Consistent top-line growth to 399.4M in 2025 (+8.7% YoY) indicates durable product demand and expanding market penetration in interventional cardiology. Over a 2–6 month horizon this supports procedure-driven adoption, distributor pull-through and scaling of commercial infrastructure.
Negative Factors
Material rise in leverage
A sudden increase to ~1.62B debt and ~6.3x debt/equity materially raises refinancing and interest burden risks. While loss-making, the company faces constrained financial flexibility; high leverage limits room for strategic investment or weathering revenue cycles over the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady revenue growth
Consistent top-line growth to 399.4M in 2025 (+8.7% YoY) indicates durable product demand and expanding market penetration in interventional cardiology. Over a 2–6 month horizon this supports procedure-driven adoption, distributor pull-through and scaling of commercial infrastructure.
Read all positive factors
MicroPort CardioFlow Medtech Corp. (2160) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.53B
Dividend YieldN/A
Average Volume (3M)8.07M
Price to Earnings (P/E)―
Beta (1Y)1.96
Revenue Growth-4.38%
EPS GrowthN/A
CountryHK
Employees430
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.49
Shares Outstanding1,273,311,400
10 Day Avg. Volume7,535,058
30 Day Avg. Volume8,069,439
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)1.49
Price to Sales (P/S)6.71
P/FCF Ratio-10.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.3
Revenue Forecast (FY)HK$2.18B
MicroPort CardioFlow Medtech Corp. Business Overview & Revenue Model
Company Description
MicroPort CardioFlow Medtech Corporation is a medical technology firm dedicated to the comprehensive research, development, and commercialization of advanced transcatheter and surgical therapies for structural heart conditions. Operating primarily...
How the Company Makes Money
MicroPort CardioFlow Medtech Corp. primarily makes money by selling medical devices and related consumables used in cardiovascular procedures to hospitals, clinics, and healthcare distributors. Revenue is generally generated from (1) direct produc...
MicroPort CardioFlow Medtech Corp. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 443.79M | 361.56M | 336.21M | 251.03M | 200.81M |
| Gross Profit | 288.34M | 251.21M | 229.93M | 162.13M | 118.70M |
| EBITDA | -111.57M | -113.32M | -386.05M | -347.91M | -173.99M |
| Net Income | -146.41M | -49.45M | -471.53M | -454.39M | -183.26M |
Balance Sheet | |||||
| Total Assets | 5.21B | 2.68B | 2.58B | 3.00B | 3.36B |
| Cash, Cash Equivalents and Short-Term Investments | 1.39B | 1.36B | 1.07B | 2.08B | 2.42B |
| Total Debt | 1.81B | 76.86M | 70.48M | 95.47M | 125.64M |
| Total Liabilities | 3.22B | 454.07M | 242.25M | 247.55M | 265.52M |
| Stockholders Equity | 1.99B | 2.19B | 2.33B | 2.75B | 3.10B |
Cash Flow | |||||
| Free Cash Flow | -297.74M | -270.06M | -237.50M | -231.60M | -269.94M |
| Operating Cash Flow | -25.82M | -111.67M | -206.99M | -182.53M | -161.50M |
| Investing Cash Flow | 404.12M | -798.50M | -596.06M | -179.78M | -437.48M |
| Financing Cash Flow | 44.33M | -56.31M | -25.61M | -136.42M | 2.23B |
MicroPort CardioFlow Medtech Corp. Technical Analysis
Negative
1.25
Price Trends
2.17
Negative
2.97
Negative
4.61
Negative
Market Momentum
-0.26
Positive
10.36
Positive
6.33
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2160, the sentiment is Negative. The current price of 1.25 is below the 20-day moving average (MA) of 1.59, below the 50-day MA of 2.17, and below the 200-day MA of 4.61, indicating a bearish trend. The MACD of -0.26 indicates Positive momentum. The RSI at 10.36 is Positive, neither overbought nor oversold. The STOCH value of 6.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2160.
MicroPort CardioFlow Medtech Corp. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | HK$1.67B | 16.82 | 7.53% | ― | 47.07% | ― | |
70 Neutral | HK$6.10B | 15.45 | 12.01% | 1.26% | 10.19% | 23.70% | |
61 Neutral | HK$6.52B | 41.10 | 4.06% | ― | 5.10% | -32.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$12.67B | 28.57 | 6.07% | ― | -3.62% | ― | |
42 Neutral | HK$582.14M | -1.22 | -21.29% | ― | -34.96% | 42.74% | |
40 Underperform | HK$1.53B | -0.81 | -7.01% | ― | -4.38% | ― |
* Healthcare Sector Average
HK:2160
MicroPort CardioFlow Medtech Corp.
1.15
-3.10
-72.94%
HK:0853
MicroPort Scientific
6.39
-1.85
-22.45%
HK:1302
LifeTech Scientific Corporation
1.45
-0.54
-27.14%
HK:1789
AK Medical Holdings Ltd.
5.24
-0.70
-11.78%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
1.24
-1.28
-50.79%
HK:6609
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
42.36
4.31
11.33%
MicroPort CardioFlow Medtech Corp. Corporate Events
MicroPort CardioFlow Grants 440,000 Share Options Under 2023 Incentive Scheme
Jun 4, 2026
MicroPort CardioFlow Medtech Corp. has granted 440,000 share options to three group employees under its share scheme adopted in 2023, allowing each option holder to subscribe for one ordinary share at an exercise price of HK$1.678. The options, wh...
MicroPort CardioFlow Wins Shareholder Backing for AGM Resolutions and Capital Mandates
Jun 4, 2026
MicroPort CardioFlow Medtech Corp. reported that all resolutions at its annual general meeting on June 4, 2026, were duly approved by shareholders via poll, including the receipt of 2025 audited financial statements. Shareholders also renewed mand...
MicroPort CardioFlow Sets Board Lineup and Committee Structure
Jun 4, 2026
MicroPort CardioFlow Medtech Corp. has announced the composition of its board of directors, led by non-executive chairman Chen Guoming and co-chairman Brian Chang, alongside executive directors Zhang Ruinian, the chief executive officer, and presi...
MicroPort CardioFlow Sets 2026 AGM, Seeks Fresh Share Buyback and Issuance Mandates
May 11, 2026
MicroPort CardioFlow Medtech Corporation has called its annual general meeting for June 4, 2026, in Shanghai, where shareholders will review the company’s audited consolidated financial statements and the reports of its directors and auditor...
MicroPort CardioFlow Wins CE Nod for Full LBBAP Pacemaker Portfolio
May 10, 2026
MicroPort CardioFlow Medtech announced that its independently developed ENO Series pacemakers have received CE approval for left bundle branch area pacing, meaning all six of its CE‑certified pacemakers are now cleared for this advanced indi...
MicroPort CardioFlow Expands Overseas Distribution Via New Connected Deals
Apr 8, 2026
MicroPort CardioFlow Medtech has entered into new 2026 international distribution framework agreements with its major shareholder MicroPort, allowing it to distribute certain cardiovascular and electrophysiology products in selected overseas regio...
MicroPort CardioFlow Revenue Rises on CRM Merger but Loss Widens in 2025
Mar 30, 2026
MicroPort CardioFlow Medtech reported 2025 revenue of USD57.0 million, up 12.6% excluding foreign exchange effects, driven by the consolidation of MicroPort CRM and a 255% surge in overseas structural heart disease sales, though gross margin slipp...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.